Protagonist Therapeutics (PTGX) Receivables - Other (2017 - 2026)

Protagonist Therapeutics has disclosed Receivables - Other across 10 years of filings, most recently posting $3.5 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $3.5 million, down 84.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 84.83% YoY), and the FY2025 annual result was $4.4 million, down 97.35% from the prior year.
• Receivables - Other came in at $3.5 million for Q1 2026 at Protagonist Therapeutics, down from $4.4 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $165.0 million in Q4 2024 to a low of $39000.0 in Q2 2023.
• The 5-year median for Receivables - Other is $3.5 million (2026), against an average of $19.2 million.
• Across the five-year window, Receivables - Other tumbled 99.8% in 2023 and surged 64353.12% in 2024, its largest moves.
• Protagonist Therapeutics' Receivables - Other stood at $42000.0 in 2022, then surged by 509.52% to $256000.0 in 2023, then soared by 64353.12% to $165.0 million in 2024, then sank by 97.35% to $4.4 million in 2025, then retreated by 20.76% to $3.5 million in 2026.
• The last three Receivables - Other figures came in at $3.5 million (Q1 2026), $4.4 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.